• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Femasys Inc. Announces the Appointment of Christine Thomas as Senior Vice President of Regulatory and Clinical Affairs

    10/12/22 8:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care
    Get the next $FEMY alert in real time by email

    ATLANTA, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced the appointment of Christine Thomas, RAC, as senior vice president of regulatory and clinical affairs, effective October 10, 2022. Ms. Thomas has over 20 years of successful leadership in regulatory and clinical affairs, including global strategy development and operations, as well as executive responsibility for medical device companies such as GE Healthcare, Boston Scientific, Smiths Medical, and RTI Surgical. Ms. Thomas will be leading all regulatory and clinical efforts for the FemBloc and FemaSeed clinical programs at Femasys.

    "We are excited about the addition of Christine to the Femasys team and the years of regulatory and clinical expertise and leadership she brings for products throughout the development cycle through commercialization, and beyond," said Kathy Lee-Sepsick, president, CEO and founder of Femasys Inc. "Christine embodies the qualities we look for in our leadership team and we are fortunate to have someone of her caliber join us as we continue to advance products to benefit women around the world."

    Ms. Thomas added, "I am pleased to join the senior leadership team at Femasys as the company continues to progress its clinical pipeline and bring more novel products to the women's health market. As senior vice president of regulatory and clinical affairs, I am excited for the opportunity to work with this great team to facilitate meaningful interactions with the Food and Drug Administration to ensure women everywhere can get access to the innovative products being advanced at Femasys."

    Ms. Thomas most recently served as head of regulatory solutions providing FDA focused consultant expertise at IQVIA MedTech, a large clinical research organization that provides solutions and services to support the needs of the medical device and in vitro diagnostics industry. Prior to this, she was vice president of regulatory, clinical, and quality at RTI Surgical, a leading surgical implant supplier. Previously, Ms. Thomas served as vice president of regulatory and clinical at Cardiac Science Corp. and vice president of regulatory, quality, compliance, regulatory and clinical, and regulatory and design assurance over her tenure at Smiths Medical. She also served as vice president/head of regulatory at Vascular Solutions and regulatory manager in the emerging therapies division at AMS. Ms. Thomas has been the regulatory, clinical, and quality lead on multiple M&A opportunities for both divestiture of product lines and acquisitions for several companies.

    Ms. Thomas holds a B.S. in Education from University of Wisconsin-Whitewater and is currently in the Johns Hopkins University Master of Science program.

    Grant of Inducement Option

    In connection with the appointment of Ms. Thomas, Femasys has granted to Ms. Thomas, effective as of her first day of employment, an option to purchase 50,000 shares of Femasys common stock at an exercise price per share equal to the closing price of Femasys common stock on the grant date as reported by Nasdaq. This grant was approved by the Compensation Committee of Femasys' Board of Directors and made as an inducement material to Ms. Thomas entering into employment with Femasys as contemplated by Nasdaq Listing Rule 5635(c)(4).

    The stock option will vest as to 25% of the shares underlying the stock option on the first anniversary of the commencement of employment, with the remaining shares vesting 25% each year over the following three years, subject to Ms. Thomas' continued employment with Femasys. Femasys provides this information in accordance with Nasdaq Listing Rule 5635(c)(4).

    About Femasys

    Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are FemBloc® permanent birth control and FemaSeed® localized directional insemination for infertility. The Company's product for fallopian tube assessment by ultrasound, FemVue®, and FemCerv®, an endocervical tissue sampler, are currently being marketed in the United States. Femasys is also advancing FemCath™, an intrauterine catheter for selective evaluation of the fallopian tubes intended to be marketed alongside its other women-specific medical products in the physician's office setting. To learn more, visit www.femasys.com or follow us on Twitter and LinkedIn.

    Forward-Looking Statements

    This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "pending," "intend," "believe," "potential" or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to develop and advance our current product candidates and programs into, and successfully initiate, enroll and complete, clinical trials; the ability of our clinical trials to demonstrate safety and effectiveness of our product candidates and other positive results; estimates regarding the total addressable market for our product candidates; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission (the "SEC") on March 24, 2022, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.

    Contacts:

    Investors

    Chuck Padala

    LifeSci Advisors, LLC

    +1-917-741-7792

    [email protected]

    Media

    Karissa Cross, Ph.D.

    LifeSci Communications

    [email protected]

    Femasys Inc.

    Investor Contact:

    [email protected]

    Media Contact:

    [email protected]



    Primary Logo

    Get the next $FEMY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $FEMY

    DatePrice TargetRatingAnalyst
    7/13/2021$18.00Buy
    JonesTrading
    7/13/2021$25.00Buy
    Chardan Capital
    More analyst ratings

    $FEMY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JonesTrading initiated coverage on Femasys with a new price target

      JonesTrading initiated coverage of Femasys with a rating of Buy and set a new price target of $18.00

      7/13/21 11:41:28 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Chardan Capital initiated coverage on Femasys with a new price target

      Chardan Capital initiated coverage of Femasys with a rating of Buy and set a new price target of $25.00

      7/13/21 8:04:59 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

      -- Milestone expands global reach and reinforces commitment to accessible, first-line infertility solutions -- ATLANTA, July 01, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products announces the achievement of regulatory approvals in Australia and New Zealand for its next-generation infertility solutions: FemaSeed® for first-line intratubal insemination treatment and FemVue® for diagnostic evaluation. "Securing regulatory approvals in Australia and New Zealand mark another important step in expand

      7/1/25 9:00:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

      ATLANTA, June 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces Conformité Européene (CE) mark certification under European Union Medical Device Regulation (EU MDR 2017/745) of the Class III FemBloc blended polymer component, marking the first regulatory approval in the world for the FemBloc® System for non-surgical female permanent birth control. After European Medicines Agency (EMA) review, the Notified Body has granted CE mark certification. The regulatory approval for the blended

      6/25/25 9:00:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

      --New CCO to Lead U.S. Commercialization of Fertility Products, Including FemaSeed®, and Expand Strategic Global Partnerships Across Full Portfolio-- ATLANTA, June 17, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the appointment of Kelley Nicholas as Chief Commercial Officer (CCO). Ms. Nicholas will be responsible for leading the execution and optimization of Femasys' commercial strategy to drive revenue growth across its entire portfolio, with a particular focus on e

      6/17/25 9:00:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Commercial Officer Nicholas Kelley Stinson

      4 - FEMASYS INC (0001339005) (Issuer)

      7/1/25 4:57:48 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • New insider Nicholas Kelley Stinson claimed ownership of 125 shares (SEC Form 3)

      3 - FEMASYS INC (0001339005) (Issuer)

      7/1/25 4:54:34 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Silverman Joshua

      4 - FEMASYS INC (0001339005) (Issuer)

      6/27/25 5:25:24 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    SEC Filings

    See more
    • Femasys Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - FEMASYS INC (0001339005) (Filer)

      7/3/25 5:22:54 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • SEC Form S-3 filed by Femasys Inc.

      S-3 - FEMASYS INC (0001339005) (Filer)

      7/3/25 5:19:58 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - FEMASYS INC (0001339005) (Filer)

      7/1/25 9:20:38 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    Leadership Updates

    Live Leadership Updates

    See more
    • Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

      --New CCO to Lead U.S. Commercialization of Fertility Products, Including FemaSeed®, and Expand Strategic Global Partnerships Across Full Portfolio-- ATLANTA, June 17, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the appointment of Kelley Nicholas as Chief Commercial Officer (CCO). Ms. Nicholas will be responsible for leading the execution and optimization of Femasys' commercial strategy to drive revenue growth across its entire portfolio, with a particular focus on e

      6/17/25 9:00:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

      ATLANTA, March 21, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing the significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, invites investors to join management in a Fireside Chat with Jones Trading Analyst Catherine Novack to discuss the current treatment landscape for infertility treatment in women. Those interested in attending the event, which will be held virtually TODAY, March 21, 2024 at 1PM ET, may register here. Femasys CEO Kathy Lee-Sepsick and Chief Medical Officer James Liu, M.D. will focus on the current treatment options in the inf

      3/21/24 9:00:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer

      -- Seasoned sales and marketing executive with 25 years of experience leading public and private healthcare companies throughout various stages of commercialization will lead commercial launch of FemaSeed -- ATLANTA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the appointment of Richard Spector to chief commercial officer (CCO), effective February 2024. Mr. Spector has 25 years of experience spanning a contin

      2/6/24 8:30:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    Financials

    Live finance-specific insights

    See more
    • Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

      -- Company delivers on mission to transform women's health with innovative solutions, including FemaSeed® for first-line infertility treatment and FemBloc® non-surgical permanent birth control (full system approval pending in Europe) -- ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the quarter ended March 31, 2025 and provides a corporate update. Corporate Highlights from 1Q 2025 to date Announced FemBloc permanent birth control delivery syste

      5/8/25 5:01:00 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

      -- Company expands commercial product offering with FemBloc® permanent birth control (delivery system) approval in Europe and signed partnerships for distribution in Spain -- ATLANTA, March 27, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the year ended December 31, 2024 and provides a corporate update. Corporate Highlights from 4Q 2024 to date Announced FemBloc® permanent birth control (delivery system) approval in Europe; FemBloc blended polymer component s

      3/27/25 9:00:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

      ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the quarter ended September 30, 2024 and provides a corporate update. Corporate Highlights from 3Q 2024 to date Announced partnership with Boston IVF, prominent network of fertility centers, to offer FemaSeed®Announced the onboarding of the first infertility medical clinic customers to offer FemaSeed infertility treatment to patients in California and FloridaAnnounced strategic distributi

      11/12/24 8:30:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Femasys Inc.

      SC 13D - FEMASYS INC (0001339005) (Subject)

      11/22/23 4:00:15 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care